The Amylin Era: Why the Next Weight-Loss Drugs Target a Different Hormone
If you've followed the GLP-1 story, 2026 added a new chapter: amylin. Both Eli Lilly and Novo Nordisk are betting heavily on amylin-based drugs as the next wave of obesity treatment. Here's what that means in plain language — and why it could matter for people who struggled with GLP-1 side effects.
What Is Amylin?
Amylin is a hormone your body releases alongside insulin. Like GLP-1, it helps curb appetite and slows how fast your stomach empties — but it works through different receptors in the brain. That difference is the whole point: because amylin and GLP-1 act on separate pathways, they can be complementary, and amylin-based drugs may produce strong weight loss with a different, often gentler side-effect profile.
The Promise: Fewer GI Side Effects
The most common reason people stop GLP-1 medications is gastrointestinal side effects — nausea, vomiting, constipation. Early research on amylin drugs suggests they may cause fewer GI side effects than pure GLP-1s while still delivering meaningful weight loss. For the large group of people who couldn't tolerate semaglutide or tirzepatide, that's a potentially big deal.
The Drugs to Know
- CagriSema (Novo Nordisk) — semaglutide + cagrilintide (GLP-1 + amylin). Furthest along: under FDA review with a decision expected in Q4 2026.
- Eloralintide (Eli Lilly) — a selective amylin receptor agonist in Phase 3, studied both alone and combined with tirzepatide.
- Petrelintide (Zealand Pharma/Roche) — a long-acting amylin analog in Phase 3.
- Zenagamtide (formerly amycretin, Novo Nordisk) — the first unimolecular GLP-1 + amylin co-agonist, in both oral and injectable forms, with strong early-phase data.
Combos vs. Standalones
Two strategies are emerging: pairing amylin with a GLP-1 (CagriSema, zenagamtide) for maximum weight loss, or standalone amylin drugs (eloralintide, petrelintide) that bet on a cleaner tolerability profile. Both approaches are advancing — which means more options tailored to different needs.
What This Means for You
- If GLP-1 side effects have been your barrier, the amylin class is worth watching.
- None of the standalone amylin drugs are approved yet — CagriSema is the closest, and it's a combination.
- Timelines slip; filing dates are not approval dates.
The Bottom Line
Amylin represents the most interesting shift in obesity medicine since tirzepatide — potentially matching GLP-1 results with fewer stomach problems. It's a few years from being fully realized, but the direction is clear. If you're on a current medication, tracking how you respond — weight, appetite, and side effects — gives you the baseline to judge whether a future amylin option would be worth switching to.
This article summarizes public reporting and research for general information and is not medical advice. Content was rephrased for compliance. Discuss treatment options with your provider.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment protocol.